Article Sidebar

PDF
Date Published: 25/04/2024
Online Published: 25/04/2024
Abstract Views: 15
Views PDF: 12
DOI: https://doi.org/10.58490/ctump.2024i73.2366
Issue
No. 73 (2024)
Section
Article
How to Cite
Tran, Q. C., & Dam, V. C. (2024). EVALUATION OF THE RESULTS OF PROSTATE CANCER TREATMENT WITH GOSERELIN ACETATE AT CAN THO CENTRAL GENERAL HOSPITAL IN 2022-2023. Cantho Journal of Medicine and Pharmacy, 73, 159-165. https://doi.org/10.58490/ctump.2024i73.2366

EVALUATION OF THE RESULTS OF PROSTATE CANCER TREATMENT WITH GOSERELIN ACETATE AT CAN THO CENTRAL GENERAL HOSPITAL IN 2022-2023

Quoc Cuong Tran1,, Van Cuong Dam2
1 Can Tho University of Medicine and Pharmacy
2 Nam Can Tho University

Main Article Content

Abstract

Background: Prostate cancer is a common disease, now there are many treatment methods such as surgery, radiotherapy, endocrine therapy, chemotherapy and immunotherapy... Hormonal treatment during stage Metastasis is the gold standard, especially when the patient is in stage IV, Androgen deprivation therapy is the first-line treatment. Objectives: To evaluate the results of prostate cancer treatment with Goserelin Acetate at Can Tho Central General Hospital in 2022-2023. Materials and methods: Cross-sectional descriptive study on 61 patients with prostate cancer prescribed androgen-deprivation therapy from January 2022 to the end of December 2023. Conduct follow-up after 6 months of treatment. Results: The most common symptom admitted to the hospital was difficulty urinating, accounting for 39.3%. After 6 months of treatment: the average difference in International Prostate Symptom Score and Quality of life scores, total blood PSA concentration, total blood testosterone concentration after treatment all decreased and this difference was statistically significant (p < 0.001). 100% of testosterone reached the threshold below < 0.5 ng/ml within 1 month of treatment. Good treatment effectiveness reached 93.4% after 6 months of treatment. There were a total of 41 unwanted effects recorded, of which the severity ranged from mild to moderate, the most common side effect being skin and subcutaneous tissue disorders accounting for 13.1%. Conclusion: Goserelin Acetate helps improve clinical and para-clinical symptoms in prostate cancer patients. Side effects of Goserelin Acetate are diverse and mild to moderate.

Article Details

Keywords

Prostate cancer, androgen-deprivation therapy (ADT), Goserelin Acetate effectiveness, Goserelin Acetate side effects

References

1. Culp MB, Soerjomataram I, Efstathiou JA, Bray F, Jemal A. Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates. Eur Urol. 2020. 77(1), 38-52, doi:
10.1016/j.eururo.2019.08.005.
2. Lowrance W, Dreicer R, Jarrard DF, Scarpato KR, Kim SK, et al. Updates to Advanced Prostate Cancer: AUA/SUO Guideline (2023). J Urol. 2023. 209(6), 1082-1090, doi: 10.1097/JU.0000000000003452.
3. Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, et al. Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023. 21(10), 10671096, doi: 10.6004/jnccn.2023.0050.
4. Schaeffer E, Srinivas S, Antonarakis ES, Armstrong AJ, Bekelman JE, et al. NCCN Guidelines Insights: Prostate Cancer, Version 1.2021. J Natl Compr Canc Netw. 2021. 19(2), 134-143, doi: 10.6004/jnccn.2021.0008.
5. Sun Y, Xie L, Xu T, Jakobsen JS, Han W, et al. Efficacy and safety of degarelix in patients with prostate cancer: Results from a phase III study in China. Asian J Urol. 2020. 7(3), 301-308, doi:
10.1016/j.ajur.2019.09.003.
6. Yikilmaz TN, Ozturk E, Hizli F, Hamidi N, Basar H. Effect of hormonal therapy for volume reduction, lower urinary tract symptom relief and voiding symptoms in prostate cancer: leuprolide vs goserelin. Urol J. 2019. 16(2), 157-161, doi: 10.22037/uj.v0i0.4245.
7. Shim M, Bang WJ, Oh CY, Lee YS, Cho JS. Effectiveness of three different luteinizing hormone-releasing hormone agonists in the chemical castration of patients with prostate cancer: Goserelin versus triptorelin versus leuprolide. Investig Clin Urol. 2019. 60(4), 244-250, doi: 10.4111/icu.2019.60.4.244.
8. Vũ Trung Kiên. Nghiên cứu ứng dụng phương pháp sinh thiết tuyến tiền liệt 12 mẫu dưới hướng dẫn siêu âm qua trực tràng trong chẩn đoán ung thư tuyến tiền liệt. Đại học Y Hà Nội. 2020. 164.
9. Tu Abrahamsson PA, Boccon-Gibod L, Morote J, de Jong IJ, Malmberg, et al. Factors Predicting the Off-treatment Duration in Patients with Prostate Cancer Receiving Degarelix as Intermittent Androgen Deprivation Therapy. Eur Urol Focus. 2017. 3(4-5), 470-479, doi:
10.1016/j.euf.2015.12.008.
10. Klarskov LL, Klarskov P, Mommsen S, Svolgaard N. Effect of endocrine treatment on voiding and prostate size in men with prostate cancer: a long-term prospective study. Scand J Urol Nephrol. 2012. 46(1), 37-43, doi: 10.3109/00365599.2011.637953.